Medullary allotransplant in acute myeloblastic leukemia in a child

Abstract Although acute myeloblastic leukemia (AML) is more resistant to chemotherapy than acute lymphoblastic leukemia (ALL), significant progresses have been achieved over the last 20 years with an improvement in the long-term survival up to 50-60%. This may be attributed to the intensification of...

Descripción completa

Detalles Bibliográficos
Autores principales: Buga Corbu, V, Glűck, R, Arion, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2014
Materias:
Young Researchers Area
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233458/
https://www.ncbi.nlm.nih.gov/pubmed/25408774
Descripción
Sumario:Abstract Although acute myeloblastic leukemia (AML) is more resistant to chemotherapy than acute lymphoblastic leukemia (ALL), significant progresses have been achieved over the last 20 years with an improvement in the long-term survival up to 50-60%. This may be attributed to the intensification of chemotherapy, including the increased use of stem-cell transplantation (HSCT) in well-defined subgroups. Allo-HSCT represents an extremely effective alternative in pediatric AML treatment panel, but its efficiency is limited both by the toxic effects and by the difficulty of finding a matched HLA donor.

Ejemplares similares